ArticleBiologics : targets & therapy2008
Rituximab in the treatment of non-Hodgkin's lymphoma.
Article in Biologics : targets & therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review.Health science reports · 2026Article
- Eosinophilic granulomatosis with polyangiitis (EGPA) on remission with a new neuropathy: a rare case of mycophenolate induced primary CNS lymphoproliferative disease.Journal of community hospital internal medicine perspectives · 2020Article
- Intravascular large B-cell lymphoma presenting as an isolated cauda equina-conus medullaris syndrome - A case report.The journal of spinal cord medicine · 2020Article
- 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2Frontiers in immunology · 2020Article
- B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis.Rheumatology international · 2019Article
- Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.Molecular cancer therapeutics · 2018Article
- Novel immunotherapies for hematologic malignancies.Immunological reviews · 2015Review
- Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma.OncoTargets and therapy · 2015Article
- Favorable outcome in non-Hodgkin lymphoma of the maxillary sinus treated with R-CHOP.Archives of medical science : AMS · 2014Article
- Structural complementation of the catalytic domain of pseudomonas exotoxin A.Journal of molecular biology · 2014Article
- Article
- A review on various targeted anticancer therapies.Targeted oncology · 2012Review
- Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy.Clinical and experimental nephrology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Besides traditional cytostatic drugs the introduction of monoclonal antibodies has substantially influenced current treatment concepts of non-Hodgkin's lymphoma (NHL). Rituximab, a monoclonal anti-CD20 chimeric antibody, now has been widely evaluated in the various B-cell lymphatic neoplasms. Large phase III studies helped to prove the value of this drug in follicular lymphoma as part of induction or relapse treatment as well as maintenance treatment. The addition of rituximab to the well established CHOP regimens has increased achievable cure rates in diffuse large cell lymphoma, and this combination is now accepted worldwide as standard of care. Although conflicting results are available, rituximab is widely used for the treatment of mantle cell lymphoma. For the less frequent lymphoma entities phase 2 studies show a considerable efficiency for most of these B-NHL variants. Current research focuses on combined chemoimmunotherapy approaches, optimization of dosing regimens, and combination with novel agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.